Trial intelligence / Profile preview

Azithromycin for treatment of COVID-19

IRCT20200415047092N1Phase 3Completed

Sponsor
Tehran University of Medical Sciences
Start
Apr 2020
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, open-label trial of azithromycin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Fever, Respiratory rate and 3 more. Started Apr 2020; status: completed.

02

Drugs

azithromycin
03

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on IRCT20200415047092N1.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on IRCT20200415047092N1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call